Lucent Diagnostics Collaborates with Tempus for Alzheimer’s Biomarker Testing
Lucent Diagnostics has partnered with Tempus AI Inc. to enhance the integration of a new blood-based biomarker panel aimed at improving the detection accuracy of Alzheimer’s disease. The collaboration will result in the development of a Tempus Next care gap program specifically for Alzheimer’s blood test.
BILLERICA, Mass.–(BUSINESS WIRE)–Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing